Cannell & Co. Mereo Biopharma Group PLC Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
Shares
2 transactions
Others Institutions Holding MREO
# of Institutions
99Shares Held
116MCall Options Held
151KPut Options Held
455K-
Janus Henderson Group PLC London, X017.1MShares$43.5 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$38.9 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$24.4 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$22.1 Million0.06% of portfolio
-
Mangrove Partners New York, NY8.64MShares$21.9 Million4.71% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $317M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...